Table 1.
Demographic and Clinical Characteristics of Patients With ASCVD by Adherence to a High‐Intensity Statin, Baseline LDL‐C, and PCSK9 Inhibitor Initiation
| Characteristic | Patient Group With ASCVD | |||
|---|---|---|---|---|
|
Adherent to High‐Intensity Statin With LDL‐C ≥70 mg/dL and Not Started on PCSK9 Inhibitor (n=13 524) |
Adherent to High‐Intensity Statin With LDL‐C ≥70 mg/dL and Started on PCSK9 Inhibitor (n=119) |
Started on PCSK9 Inhibitor Without Adherence to High‐Intensity Statin and/or With LDL‐C <70 mg/dL (n=1049) |
P Value | |
| Age, mean (SD), y | 57.0 (5.9) | 56.0 (6.5) | 57.0 (6.3) | 0.053 |
| Women | 4015 (29.7) | 32 (26.9) | 401 (38.2) | <0.001 |
| Region | 0.63 | |||
| Northeast | 1368 (10.1) | 13 (10.9) | 108 (10.3) | |
| Midwest | 1767 (13.1) | 13 (10.9) | 118 (11.3) | |
| South | 7858 (58.1) | 68 (57.1) | 615 (58.6) | |
| West | 2503 (18.5) | 24 (20.2) | 205 (19.5) | |
| Unknown | 28 (0.2) | 1 (0.8) | 3 (0.3) | |
| Race/ethnicity | <0.001 | |||
| White | 8566 (63.3) | 92 (77.3) | 700 (66.7) | |
| Black | 1384 (10.2) | 10 (8.4) | 91 (8.7) | |
| Hispanic | 1258 (9.3) | 9 (7.6) | 116 (11.1) | |
| Asian | 321 (2.4) | 1 (0.8) | 30 (2.9) | |
| Unknown | 1995 (14.8) | 7 (5.9) | 112 (10.7) | |
| Cardiovascular risk factors | ||||
| Premature ASCVD | 5053 (37.4) | 51 (42.9) | 405 (38.6) | 0.35 |
| MACE in past year | 3811 (28.2) | 22 (19.3) | 196 (18.7) | <0.001 |
| Coronary artery disease | 11 251 (83.2) | 114 (95.8) | 975 (93.0) | <0.001 |
| Stroke/TIA | 2395 (17.7) | 7 (5.9) | 94 (9.0) | <0.001 |
| Peripheral arterial disease | 3006 (22.2) | 24 (20.2) | 219 (20.9) | 0.52 |
| Diabetes mellitus | 5923 (43.8) | 39 (32.8) | 411 (39.2) | 0.001 |
| Hypertension | 11 661 (86.2) | 97 (81.5) | 880 (83.9) | 0.04 |
| Baseline medications | ||||
| Ezetimibe | 911 (6.7) | 66 (55.5) | 331 (31.6) | <0.001 |
| Bile acid sequestrants | 148 (1.1) | 10 (8.4) | 53 (5.1) | <.001 |
| Fibrates | 1478 (10.9) | 17 (14.3) | 123 (11.7) | 0.38 |
| Use | ||||
| Outpatient cardiology visit | 10 137 (75.0) | 95 (79.8) | 930 (88.7) | <0.001 |
| No. of cardiology visits, median (IQR) | 2 (0–4) | 3 (1–5) | 3 (2–6) | <0.001 |
| Baseline LDL‐C, mg/dL | <0.001 | |||
| <70 | N/A | N/A | 154 (14.7) | |
| 70–99 | 9920 (73.4) | 33 (27.7) | 146 (13.9) | |
| 100–129 | 2610 (19.3) | 38 (31.9) | 220 (21.0) | |
| ≥130 | 994 (7.4) | 48 (40.3) | 529 (50.4) | |
Data are given as number (percentage) of each group, unless otherwise indicated. ASCVD indicates atherosclerotic cardiovascular disease; IQR, interquartile range; LDL‐C, low‐density lipoprotein cholesterol; MACE, major adverse cardiovascular event; N/A, not applicable; PCSK9, proprotein convertase subtilisin/kexin type 9; and TIA, transient ischemic attack.